Can This Year Be A Good Year For Marijuana Stocks?

GWPH Chart

The company plans to announce phase 3 results from its first cancer study early next year, with results from a second phase 3 study expected in the second quarter. If those results are positive, GW Pharma hopes to file for FDA approval in the second half of next year; with the agency’s OK, Sativex could reach the U.S. market in 2016. GW Pharma should also provide investors with more insight into its epilepsy programs in 2015.

In October, the company kicked off Part A of its phase 2/3 trial in Dravet Syndrome, and Part B will begin in the first quarter. GW Pharma further plans to launch two phase 3 studies for Epidiolex in Lennox-Gastaut syndrome, or LGS, early next year. Most investors will focus on Sativex and Epidiolex, but they should also pay attention to GW Pharma’s phase 2a trial of GWP42003 for use as a schizophrenia treatment.

That trial should be complete in the second half of 2015. Expanding its franchise Similarly to GW Pharma, Insys has a full slate of catalysts that could move shares higher or lower next year.

To read more, visit

Comments are closed.

Get the latest content first.
©Marijuana Stocks Report